Baxdrostat - CinCor Pharma
Alternative Names: CIN-107Latest Information Update: 04 Sep 2025
At a glance
- Originator Roche
- Developer AstraZeneca; CinCor Pharma; CinRx Pharma
- Class Amides; Antihypertensives; Antisecretories; Isoquinolines; Small molecules
- Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension; Renal failure
- Phase II Hyperaldosteronism
- No development reported Spinal cord disorders
Most Recent Events
- 30 Aug 2025 Efficacy and adverse events data from phase III trial in Hypertension releases by AstraZeneca
- 14 Jul 2025 Efficacy and adverse events data from the phase III BaxHTN trial in Hypertension released by AstraZeneca
- 06 Jun 2025 AstraZeneca plans a phase III trial for Hyperaldosteronism in Canada, Germany, Italy, Spain, United Kingdom (PO) (NCT07007793)